PE20130643A1 - Conjugados de anticuerpos multifuncionales - Google Patents

Conjugados de anticuerpos multifuncionales

Info

Publication number
PE20130643A1
PE20130643A1 PE2013000052A PE2013000052A PE20130643A1 PE 20130643 A1 PE20130643 A1 PE 20130643A1 PE 2013000052 A PE2013000052 A PE 2013000052A PE 2013000052 A PE2013000052 A PE 2013000052A PE 20130643 A1 PE20130643 A1 PE 20130643A1
Authority
PE
Peru
Prior art keywords
seq
antibody
conjugate
combivalizumab
covalently connected
Prior art date
Application number
PE2013000052A
Other languages
English (en)
Inventor
Abhijit Suresh Bhat
Curt William Bradshaw
Oliver Alexandre Laurent
Alice Lee
Richard Ryan Preston
David Tumelty
Lauren Diane Wood
Wei Hong Yu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of PE20130643A1 publication Critical patent/PE20130643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN CONJUGADO DEL ANTICUERPO MULTIFUNCIONAL (MAC) QUE COMPRENDE: (i) UN ANTICUERPO, O PORCION DE ANTIGENO DEL MISMO SELECCIONADO ENTE RITUXIMAB, CETIXIMAB, INFLIXIMAB, ADALIMUMAB, NATALIZUMAB, OMALIZUMAB, RANIBIZUMAB Y PALIVIZUMAB, QUE COMPRENDE AL MENOS UN FRAGMENTO DE UNA REGION KAPPA CONSTANTE DE CADENA LIGERA (CLk), QUE COMPRENDE AL MENOS LOS RESTOS 1 A 106 DE LA SEC ID N° 15, SEC ID N° 45, SEC ID N° 46 O SEC ID N° 47; (ii) UN ENGARCE QUE COMPRENDE LA FORMULA X-Y-Z, DONDE Z ES UN GRUPO QUE ESTA CONECTADO COVALENTEMENTE AL ANTICUERPO; Y ES UNA CADENA DE CONEXION BIOLOGICAMENTE COMPATIBLE LINEAL O RAMIFICADA; X ES UN GRUPO CONECTADO COVALENTEMENTE AL MENOS UN RESTO EFECTOR EL CUAL ES UNA PROTEINA O UN PEPTIDO DE UNION A ANG2 QUE COMPRENDE LA SECUENCIA SEC ID N° 27,28, 29 ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DEL CONJUGADO. DICHO CONJUGADO DE ANTICUERPO PROPORCIONA EL BENEFICIO DE LA TERAPIA BIFUNCIONAL EN EL TRATAMIENTO DE CANCER.
PE2013000052A 2010-07-12 2011-07-11 Conjugados de anticuerpos multifuncionales PE20130643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36350710P 2010-07-12 2010-07-12

Publications (1)

Publication Number Publication Date
PE20130643A1 true PE20130643A1 (es) 2013-06-07

Family

ID=44630490

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000052A PE20130643A1 (es) 2010-07-12 2011-07-11 Conjugados de anticuerpos multifuncionales

Country Status (18)

Country Link
US (1) US8741291B2 (es)
EP (1) EP2593142B8 (es)
JP (2) JP5913307B2 (es)
KR (1) KR20130050966A (es)
CN (1) CN103096933A (es)
AR (1) AR082205A1 (es)
AU (1) AU2011277999A1 (es)
BR (1) BR112013000951A2 (es)
CA (1) CA2804185C (es)
CO (1) CO6670522A2 (es)
ES (1) ES2704223T3 (es)
MX (1) MX2013000491A (es)
PE (1) PE20130643A1 (es)
RU (1) RU2012157167A (es)
SG (1) SG186451A1 (es)
TW (1) TWI432213B (es)
WO (1) WO2012007896A1 (es)
ZA (1) ZA201300161B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013005075A (es) 2010-11-05 2013-05-28 Pfizer Compuestos antidiabeticos.
CN103648532A (zh) * 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
KR101733853B1 (ko) 2011-11-17 2017-05-08 화이자 인코포레이티드 세포독성 펩티드 및 그의 항체 약물 접합체
CA2863216C (en) 2012-01-09 2020-06-02 Covx Technologies Ireland Limited Mutant antibodies and conjugation thereof
SI3342785T1 (sl) 2012-10-11 2020-02-28 Daiichi Sankyo Company, Limited Povezovalci za konjugate protitelesa in zdravila
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
TWI589590B (zh) 2012-11-07 2017-07-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
WO2014072888A1 (en) 2012-11-07 2014-05-15 Pfizer Inc. Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
SG11201502876RA (en) 2012-11-08 2015-06-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015057063A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
EP3929301A1 (en) * 2013-10-14 2021-12-29 SynAffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP3088419B1 (en) 2013-12-25 2018-10-10 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
CN110464847B (zh) * 2014-01-31 2024-02-09 第一三共株式会社 抗her2抗体－药物偶联物
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
SG10201907807XA (en) 2014-04-10 2019-09-27 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
CN107249631B (zh) 2014-11-07 2021-11-23 十一生物治疗股份有限公司 改进的il-6抗体
US9994638B2 (en) * 2015-05-20 2018-06-12 Immunwork Inc. Peptide core-based multi-arm linkers for treating infectious diseases
HUE051315T2 (hu) * 2015-06-19 2021-03-01 Eisai R&D Man Co Ltd Cys80 helyzetben konjugált immunglobulinok
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
CA2998740A1 (en) * 2015-09-17 2017-03-23 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
EA201890941A1 (ru) * 2015-10-23 2018-11-30 Сорренто Терапьютикс, Инк. Программируемые универсальные клеточные рецепторы и способы их применения
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
CA3013829A1 (en) 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity labels
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
US11434289B2 (en) 2017-01-17 2022-09-06 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
AU2018211561B2 (en) 2017-01-24 2020-04-30 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
IL272964B2 (en) 2017-08-31 2024-02-01 Daiichi Sankyo Co Ltd Production method for antibody-drug conjugates
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
CN113330029A (zh) * 2019-08-19 2021-08-31 沈阳药科大学 抗体的突变体及其应用
CA3151662A1 (en) 2019-09-04 2021-03-11 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
KR20240035825A (ko) 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN118201640A (zh) * 2021-11-01 2024-06-14 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物
AU2023254846A1 (en) 2022-04-15 2024-10-10 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
IL315944A (en) * 2022-04-15 2024-11-01 Dyne Therapeutics Inc Muscle targeting complexes and their uses for the treatment of myotonic dystrophy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
AU7872300A (en) 1999-10-08 2001-04-23 Scripps Research Institute, The Antibody catalysis of enantio- and diastereo-selective aldol reactions
AP2072A (en) 2001-01-05 2009-12-10 Pfizer Antibodies to insulin-like growth factor I receptor
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
PT1656391E (pt) 2003-08-13 2010-12-06 Pfizer Prod Inc Anticorpos humanos modificados contra igf-ir
CA2598833A1 (en) 2005-03-03 2006-09-08 Curt W. Bradshaw Anti-angiogenic compounds
NZ576751A (en) * 2006-11-10 2011-10-28 Covx Technologies Ireland Ltd Anti-angiogenic compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
EP2237797A4 (en) 2008-01-03 2012-11-07 Scripps Research Inst TARGETING ANTIBODIES BY MODULAR RECOGNITION DOMAIN
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies

Also Published As

Publication number Publication date
AR082205A1 (es) 2012-11-21
EP2593142A1 (en) 2013-05-22
RU2012157167A (ru) 2014-08-20
JP6339995B2 (ja) 2018-06-06
JP2013534535A (ja) 2013-09-05
JP2016094455A (ja) 2016-05-26
EP2593142B8 (en) 2018-12-26
KR20130050966A (ko) 2013-05-16
MX2013000491A (es) 2013-02-26
ZA201300161B (en) 2013-09-25
CN103096933A (zh) 2013-05-08
CA2804185A1 (en) 2012-01-19
CA2804185C (en) 2017-03-21
WO2012007896A1 (en) 2012-01-19
CO6670522A2 (es) 2013-05-15
JP5913307B2 (ja) 2016-04-27
SG186451A1 (en) 2013-01-30
TW201216986A (en) 2012-05-01
BR112013000951A2 (pt) 2016-05-17
US8741291B2 (en) 2014-06-03
TWI432213B (zh) 2014-04-01
ES2704223T3 (es) 2019-03-15
EP2593142B1 (en) 2018-10-10
US20120201809A1 (en) 2012-08-09
AU2011277999A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
PE20130643A1 (es) Conjugados de anticuerpos multifuncionales
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
PE20171512A1 (es) Anticuerpos anti-fap
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20091112A1 (es) Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
RU2013138469A (ru) АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
AR092216A1 (es) Formulaciones estables de anticuerpos contra tslp
NZ719036A (en) Anti-pdl1 antibody formulations
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
MY182680A (en) Antibody formulation and therapeutic regimens
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4

Legal Events

Date Code Title Description
FD Application declared void or lapsed